PROPEL: a randomized, phase Ill trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors
Clarke, Noel WArmstrong, AJ
Thiery-Vuillemin, A
Oya, M
Ye, DW
Mateo, J
Goessl, CD
Kang, JY
Liu, S
Saad, F
Affiliation
The Christie and Salford Royal Hospitals, ManchesterIssue Date
2019
Metadata
Show full item recordCitation
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Ye D, Mateo J, et al. PROPEL: a randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37(7_suppl):TPS340-TPS.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2019.37.7_suppl.TPS340Additional Links
https://dx.doi.org/ 10.1200/JCO.2019.37.7_suppl.TPS340Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2019.37.7_suppl.TPS340